Impaler Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 8 Year, 5 Days
- Last Filing with ROC 31 Mar 2020
- Open Charges ₹ 0.20 M
- Revenue Growth -57.81%
- Profit Growth -24.74%
- Ebitda 1741.32%
- Net Worth 4.26%
- Total Assets 109.66%
About Impaler Pharmaceuticals
Impaler Pharmaceuticals Private Limited (IPPL) is a Private Limited Indian Non-Government Company incorporated in India on 20 February 2017 (Eight years 5 days old ). Its registered office is in Nagpur, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹0.20 M.
Nikhil Meshram, Chandramani Meshram, and Shailja Meshram serve as directors at the Company.
Company Details
- Location
Nagpur, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U52100MH2017PTC291432
- Company No.
291432
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Feb 2017
- Date of AGM
28 Dec 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Impaler Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nikhil Meshram  | Managing Director | 20-Feb-2017 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Chandramani Meshram | Additional Director | 26-Nov-2020 | Current |
| Shailja Meshram | Additional Director | 05-Dec-2020 | Current |
Financial Performance of Impaler Pharmaceuticals.
Impaler Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 57.81% decrease. The company also saw a substantial fall in profitability, with a 24.74% decrease in profit. The company's net worth moved up by a moderate rise of 4.26%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Impaler Pharmaceuticals?
In 2018, Impaler Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0.20 M
₹0
Charges Breakdown by Lending Institutions
- Syndicate Bank : 0.02 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 12 Dec 2017 | Syndicate Bank | ₹0.20 M | Open |
How Many Employees Work at Impaler Pharmaceuticals?
Unlock and access historical data on people associated with Impaler Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Impaler Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Impaler Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
